Yi Cui

Yi Cui has extensive work experience in the pharmaceutical and medical research fields. They currently hold the position of Medical Director at Achilles Therapeutics plc since February 2022. Prior to that, they were the Vice President and Head of Clinical Drug Safety & Pharmacovigilance at Freeline starting in 2021. Before joining Freeline, Yi Cui worked at GSK as the Director of Early Phase and Cell Gene Therapy from an unspecified date in 2017 until July 2021. They also held various managerial and research roles at GSK, including Manager of SERM and Head of Electrophysiology Assessment, In Vitro/In Vivo Translation. Prior to GSK, Yi Cui worked as a Senior Research Fellow at University College London and as a Post-doc at the University of Oxford.

Yi Cui holds a Bachelor of Medicine degree in Medicine and a PhD in Pharmacology, both from The Fourth Military Medical University.